 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || PM1021 / Biotheus, Adimab, PM8001 / Biotheus
Trial initiation date, Combination therapy, Monotherapy, Metastases: A Study of PM1021 (Anti-TIGIT) With or Without PM8001 (Anti-PD-L1/TGF-?) in Patients With Advanced Solid Tumours (clinicaltrials.gov) - Feb 8, 2023
P1, N=30, Not yet recruiting, Sponsor: Biotheus Inc.
Initiation date: Dec 2022 --> Oct 2023
- | PM1021 / Biotheus, Adimab, PM8001 / Biotheus
New P1 trial, Combination therapy, Monotherapy, Metastases: A Study of PM1021 (Anti-TIGIT) With or Without PM8001 (Anti-PD-L1/TGF-?) in Patients With Advanced Solid Tumours (clinicaltrials.gov) - Sep 13, 2022
P1, N=30, Not yet recruiting, Sponsor: Biotheus Inc.
- PM8001 / Biotheus
Phase I/IIa study of PM8001, a bifunctional fusion protein targeting PD-L1 and TGF‑β, in patients with advanced tumors. (Available On Demand; 168) - Apr 28, 2022 - Abstract #ASCO2022ASCO_1557;
PM8001 showed an acceptable safety profile and promising anti-tumor activity in advanced solid tumors, especially in patients previously treated with checkpoint inhibitors, which supports further studies to explore the safety and efficacy of PM8001 as a monotherapy and in combination with other anti-tumor agents. Global Phase II monotherapy and combination studies are currently ongoing.